

Sanofi  
Form 6-K  
January 07, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of January 2019**

**Commission File Number: 001-31368**

**SANOFI**

**(Translation of registrant's name into English)**

**54, rue La Boétie, 75008 Paris, FRANCE**

**(Address of principal executive offices)**

Edgar Filing: Sanofi - Form 6-K

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If ☐ Yes ☐ marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

In December 2018 and January 2019, Sanofi issued the press releases attached hereto as Exhibit 99.1, 99.2 and 99.3 which are incorporated herein by reference.

**Exhibit List**

Exhibit No.	Description
Exhibit 99.1	Press release dated January 7, 2019: Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
Exhibit 99.2	Press release dated December 26, 2018: FDA Approves VAXELIS , Sanofi and MSD s Pediatric Hexavalent Combination Vaccine
Exhibit 99.3	Press release dated December 19, 2018: Dengvaxia® vaccine approved for prevention of dengue in Europe

**Exhibit Index**

Exhibit No.	Description
Exhibit 99.1	Press release dated January 7, 2019: Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
Exhibit 99.2	Press release dated December 26, 2018: FDA Approves VAXELIS , Sanofi and MSD 's Pediatric Hexavalent Combination Vaccine
Exhibit 99.3	Press release dated December 19, 2018: Dengvaxia® vaccine approved for prevention of dengue in Europe

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: January 7, 2019

SANOFI

By /s/ Alexandra Roger

Name: Alexandra Roger

Title: Head of Securities Law and Capital Markets